fbpx
Wikipedia

Oncostatin M receptor

January 01, 1970

Oncostatin-M specific receptor subunit beta also known as the Oncostatin M receptor (OSMR) , is one of the receptor proteins for oncostatin M, that in humans is encoded by the OSMR gene.[5][6]

OSMR
Identifiers
AliasesOSMR, OSMRB, PLCA1, IL-31R-beta, IL-31RB, oncostatin M receptor, OSMRbeta
External IDsOMIM: 601743; MGI: 1330819; HomoloGene: 2972; GeneCards: OSMR; OMA:OSMR - orthologs
Orthologs
SpeciesHumanMouse
Entrez

9180

18414

Ensembl

ENSG00000145623

ENSMUSG00000022146

UniProt

Q99650

O70458

RefSeq (mRNA)

NM_011019
NM_001310469

RefSeq (protein)

NP_001297398
NP_035149

Location (UCSC)Chr 5: 38.85 – 38.95 MbChr 15: 6.84 – 6.9 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

OSMR is a member of the type I cytokine receptor family. This protein heterodimerizes with interleukin 6 signal transducer to form the type II oncostatin M receptor and with interleukin 31 receptor A to form the interleukin 31 receptor, and thus transduces oncostatin M and interleukin 31 induced signaling events.[5]

Expression edit

OSMR is widely expressed across non-haematopoietic, hepatocytes, mesothelial cells, glial cells and epithelial cell types across various organs and mammary glands.[7] OSM receptor is abundantly expressed on endothelial and stromal/fibroblast cells in the lung of mice.[8]=

In vitro expression of OSMR  in fetal hepatocytes is upregulated by OSM stimulation.[9]

OSMR expression has been shown to be induced by parathyroid hormone in osteoblasts and OSM.[10][11]

Signaling edit

Intracellular cell signalling occurs as a consequence of extracellular binding of the ligand OSM to OSMR complexes, formed from dimerization with receptor subunits such as gp130. Activation of the OSMR-gp130 complex by OSM triggers Janus Kinase 1 (JAK1) and Jak2 cross phosphorylation of tyrosine residues on the intracellular receptor domain. Downstream signaling activation of the OSMR-gp130 complex  along the JAK1 pathway leads to IL-6 signalling which is linked with activation of the MAPK cascade, PI3K cascade and STAT3 activation.[12][13]

OSM induced recruitment of SHC to the OSMRβ sub-unit has been shown to enhance Ras/Raf/MAPK signaling and lead p38 and JNK activation.[14]

Clinical significance edit

The oncostatin M receptor is associated with primary cutaneous amyloidosis.[15]

OSM signaling via the OSMR is believed to play an important role in bone turnover as Mice lacking the OSMR receptor have osteopetrotic phenotypes.[16] Lack of OSMRβ activity has also been linked to adipose tissue inflammation and insulin resistance preceding obesity.[17]

OSM in-vivo regulation of hematopoiesis, through stimulation of stromal cells & hematopoietic progenitors - megakaryocytic and erythrocytic progenitors, is carried out by the OSMRβ receptor.[18]

Heart Disease edit

Inhibition of the OSMRβ extracellular subunit has been shown has been shown to prevent OSM-mediated down-regulation of myoglobin in cardiomyocytes and related apoptosis of cardiomyocytes in inflammatory heart failure.[19]

OSMRβ is not only overexpressed in patients with chronic dilated cardiomyopathy but has been shown to control dedifferentiation and loss of sarcomeric structures in myocardial infarction and dilated cardio myopathy.[20] OSM and OSMRβ mediated dedifferentiation  has been shown to increase chances of survival after acute myocardial damage but poor survival rates and compromised pump functions in chronic disease states.[20]

Cancer edit

OSMR activates STAT3 and transforming growth factor β (TGF-β) effector SMAD3 to regulate expression of genes responsible for inducing a mesenchymal/CSC phenotype.[21]

OSM-induced biological effects on breast tumor– derived cell lines were specifically mediated through the gp130/OSMRB complex.[22]

the OSM receptor (OSMR) is overexpressed in cervical squamous cell carcinomas and, independent of tumor stage, is associated with adverse clinical outcomes and higher relative risk of death.[23]

OSM and OSMRβ are co-expressed and lead to STAT 3 activation malignant human ovarian epithelial cells.[24]

The OSMR β  promoter gene is highly methylated in primary Colorectal Cancer tissues and  fecal DNA, it is a highly specific diagnostic biomarker of Colorectal Cancer.[25]

References edit

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000145623 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000022146 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: oncostatin M receptor".
  6. ^ Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D (December 1996). "Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation". The Journal of Biological Chemistry. 271 (51): 32635–43. doi:10.1074/jbc.271.51.32635. PMID 8999038.
  7. ^ West NR, Owens BM, Hegazy AN (September 2018). "The oncostatin M-stromal cell axis in health and disease". Scandinavian Journal of Immunology. 88 (3): e12694. doi:10.1111/sji.12694. PMID 29926972.
  8. ^ Machiyama T, So T, Okuyama Y, Kobayashi S, Phung HT, Asao A, Harigae H, Ishii N (May 2018). "TNF receptor associated factor 5 controls oncostatin M-mediated lung inflammation". Biochemical and Biophysical Research Communications. 499 (3): 544–550. doi:10.1016/j.bbrc.2018.03.186. PMID 29596835.
  9. ^ Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E, Nakashima K, Taga T, Yoshida K, Kishimoto T, Miyajima A (April 1999). "Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer". The EMBO Journal. 18 (8): 2127–36. doi:10.1093/emboj/18.8.2127. PMC 1171297. PMID 10205167.
  10. ^ Walker EC, Poulton IJ, McGregor NE, Ho PW, Allan EH, Quach JM, Martin TJ, Sims NA (April 2012). "Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo". Journal of Bone and Mineral Research. 27 (4): 902–12. doi:10.1002/jbmr.1506. PMID 22190112. S2CID 3475348.
  11. ^ Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H (December 2001). "Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms". The Journal of Biological Chemistry. 276 (50): 47038–45. doi:10.1074/jbc.M107971200. PMID 11602599.
  12. ^ Hunter CA, Jones SA (May 2015). "IL-6 as a keystone cytokine in health and disease". Nature Immunology. 16 (5): 448–57. doi:10.1038/ni.3153. PMID 25898198. S2CID 205369252.
  13. ^ Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (August 2003). "Principles of interleukin (IL)-6-type cytokine signalling and its regulation". The Biochemical Journal. 374 (Pt 1): 1–20. doi:10.1042/bj20030407. PMC 1223585. PMID 12773095.
  14. ^ Hermanns HM, Radtke S, Schaper F, Heinrich PC, Behrmann I (December 2000). "Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to the oncostatin M receptor". The Journal of Biological Chemistry. 275 (52): 40742–8. doi:10.1074/jbc.M005408200. PMID 11016927.
  15. ^ Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA (January 2008). "Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis". American Journal of Human Genetics. 82 (1): 73–80. doi:10.1016/j.ajhg.2007.09.002. PMC 2253984. PMID 18179886.
  16. ^ Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA (February 2010). "Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice". The Journal of Clinical Investigation. 120 (2): 582–92. doi:10.1172/jci40568. PMC 2810087. PMID 20051625.
  17. ^ Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y (July 2013). "Lack of oncostatin M receptor β leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype". The Journal of Biological Chemistry. 288 (30): 21861–75. doi:10.1074/jbc.M113.461905. PMC 3724642. PMID 23760275.
  18. ^ Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A (November 2003). "Targeted disruption of oncostatin M receptor results in altered hematopoiesis". Blood. 102 (9): 3154–62. doi:10.1182/blood-2003-02-0367. PMID 12855584.
  19. ^ Pöling J, Gajawada P, Richter M, Lörchner H, Polyakova V, Kostin S, Shin J, Boettger T, Walther T, Rees W, Wietelmann A, Warnecke H, Kubin T, Braun T (January 2014). "Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure". Basic Research in Cardiology. 109 (1): 396. doi:10.1007/s00395-013-0396-3. PMID 24292852. S2CID 21889689.
  20. ^ a b Kubin T, Pöling J, Kostin S, Gajawada P, Hein S, Rees W, Wietelmann A, Tanaka M, Lörchner H, Schimanski S, Szibor M, Warnecke H, Braun T (November 2011). "Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling". Cell Stem Cell. 9 (5): 420–32. doi:10.1016/j.stem.2011.08.013. PMID 22056139.
  21. ^ Junk DJ, Bryson BL, Smigiel JM, Parameswaran N, Bartel CA, Jackson MW (July 2017). "Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling". Oncogene. 36 (28): 4001–4013. doi:10.1038/onc.2017.33. PMC 5509502. PMID 28288136.
  22. ^ Underhill-Day N, Heath JK (November 2006). "Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel". Cancer Research. 66 (22): 10891–901. doi:10.1158/0008-5472.CAN-06-1766. PMID 17108126.
  23. ^ Ng G, Winder D, Muralidhar B, Gooding E, Roberts I, Pett M, Mukherjee G, Huang J, Coleman N (July 2007). "Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome". The Journal of Pathology. 212 (3): 325–34. doi:10.1002/path.2184. PMID 17516585. S2CID 21134882.
  24. ^ Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ, Nelson BE (March 2002). "Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas". Cytokine. 17 (6): 324–34. doi:10.1006/cyto.2002.1022. PMID 12061840.
  25. ^ Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, Yamashita K, Liu J, Ostrow KL, Ling S, Guerrero-Preston R, Demokan S, Yalniz Z, Dalay N, Meijer GA, Van Criekinge W, Sidransky D (August 2009). "Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer". PLOS ONE. 4 (8): e6555. Bibcode:2009PLoSO...4.6555K. doi:10.1371/journal.pone.0006555. PMC 2717211. PMID 19662090.

External links edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

January 01, 1970
oncostatin, receptor, oncostatin, specific, receptor, subunit, beta, also, known, osmr, receptor, proteins, oncostatin, that, humans, encoded, osmr, gene, osmridentifiersaliasesosmr, osmrb, plca1, beta, 31rb, oncostatin, receptor, osmrbetaexternal, idsomim, 60. Oncostatin M specific receptor subunit beta also known as the Oncostatin M receptor OSMR is one of the receptor proteins for oncostatin M that in humans is encoded by the OSMR gene 5 6 OSMRIdentifiersAliasesOSMR OSMRB PLCA1 IL 31R beta IL 31RB oncostatin M receptor OSMRbetaExternal IDsOMIM 601743 MGI 1330819 HomoloGene 2972 GeneCards OSMR OMA OSMR orthologsGene location Human Chr Chromosome 5 human 1 Band5p13 1Start38 845 858 bp 1 End38 945 596 bp 1 Gene location Mouse Chr Chromosome 15 mouse 2 Band15 A1 15 3 3 cMStart6 843 058 bp 2 End6 904 450 bp 2 RNA expression patternBgeeHumanMouse ortholog Top expressed inpericardiumsaphenous veintibialower lobe of lungright ventricleperitoneumvisceral pleuraparietal pleurasuperficial temporal arterystromal cell of endometriumTop expressed inretinal pigment epitheliumconjunctival fornixciliary bodyright lung lobePaneth cellcarotid bodycorneal stromasubcutaneous adipose tissuecalvariairisMore reference expression dataBioGPSn aGene ontologyMolecular functioncytokine receptor activity oncostatin M receptor activity growth factor binding cytokine binding protein bindingCellular componentintegral component of membrane oncostatin M receptor complex plasma membrane apical plasma membrane membrane external side of plasma membrane receptor complexBiological processpositive regulation of acute inflammatory response response to cytokine oncostatin M mediated signaling pathway positive regulation of cell population proliferation cytokine mediated signaling pathwaySources Amigo QuickGOOrthologsSpeciesHumanMouseEntrez918018414EnsemblENSG00000145623ENSMUSG00000022146UniProtQ99650O70458RefSeq mRNA NM 001168355NM 003999NM 001323504NM 001323505NM 001323506NM 001323507NM 011019NM 001310469RefSeq protein NP 001161827NP 001310433NP 001310434NP 001310435NP 001310436NP 003990NP 001297398NP 035149Location UCSC Chr 5 38 85 38 95 MbChr 15 6 84 6 9 MbPubMed search 3 4 WikidataView Edit HumanView Edit Mouse OSMR is a member of the type I cytokine receptor family This protein heterodimerizes with interleukin 6 signal transducer to form the type II oncostatin M receptor and with interleukin 31 receptor A to form the interleukin 31 receptor and thus transduces oncostatin M and interleukin 31 induced signaling events 5 Contents 1 Expression 2 Signaling 3 Clinical significance 3 1 Heart Disease 3 2 Cancer 4 References 5 External linksExpression editOSMR is widely expressed across non haematopoietic hepatocytes mesothelial cells glial cells and epithelial cell types across various organs and mammary glands 7 OSM receptor is abundantly expressed on endothelial and stromal fibroblast cells in the lung of mice 8 In vitro expression of OSMR in fetal hepatocytes is upregulated by OSM stimulation 9 OSMR expression has been shown to be induced by parathyroid hormone in osteoblasts and OSM 10 11 Signaling editIntracellular cell signalling occurs as a consequence of extracellular binding of the ligand OSM to OSMR complexes formed from dimerization with receptor subunits such as gp130 Activation of the OSMR gp130 complex by OSM triggers Janus Kinase 1 JAK1 and Jak2 cross phosphorylation of tyrosine residues on the intracellular receptor domain Downstream signaling activation of the OSMR gp130 complex along the JAK1 pathway leads to IL 6 signalling which is linked with activation of the MAPK cascade PI3K cascade and STAT3 activation 12 13 OSM induced recruitment of SHC to the OSMRb sub unit has been shown to enhance Ras Raf MAPK signaling and lead p38 and JNK activation 14 Clinical significance editThe oncostatin M receptor is associated with primary cutaneous amyloidosis 15 OSM signaling via the OSMR is believed to play an important role in bone turnover as Mice lacking the OSMR receptor have osteopetrotic phenotypes 16 Lack of OSMRb activity has also been linked to adipose tissue inflammation and insulin resistance preceding obesity 17 OSM in vivo regulation of hematopoiesis through stimulation of stromal cells amp hematopoietic progenitors megakaryocytic and erythrocytic progenitors is carried out by the OSMRb receptor 18 Heart Disease edit Inhibition of the OSMRb extracellular subunit has been shown has been shown to prevent OSM mediated down regulation of myoglobin in cardiomyocytes and related apoptosis of cardiomyocytes in inflammatory heart failure 19 OSMRb is not only overexpressed in patients with chronic dilated cardiomyopathy but has been shown to control dedifferentiation and loss of sarcomeric structures in myocardial infarction and dilated cardio myopathy 20 OSM and OSMRb mediated dedifferentiation has been shown to increase chances of survival after acute myocardial damage but poor survival rates and compromised pump functions in chronic disease states 20 Cancer edit OSMR activates STAT3 and transforming growth factor b TGF b effector SMAD3 to regulate expression of genes responsible for inducing a mesenchymal CSC phenotype 21 OSM induced biological effects on breast tumor derived cell lines were specifically mediated through the gp130 OSMRB complex 22 the OSM receptor OSMR is overexpressed in cervical squamous cell carcinomas and independent of tumor stage is associated with adverse clinical outcomes and higher relative risk of death 23 OSM and OSMRb are co expressed and lead to STAT 3 activation malignant human ovarian epithelial cells 24 The OSMR b promoter gene is highly methylated in primary Colorectal Cancer tissues and fecal DNA it is a highly specific diagnostic biomarker of Colorectal Cancer 25 References edit a b c GRCh38 Ensembl release 89 ENSG00000145623 Ensembl May 2017 a b c GRCm38 Ensembl release 89 ENSMUSG00000022146 Ensembl May 2017 Human PubMed Reference National Center for Biotechnology Information U S National Library of Medicine Mouse PubMed Reference National Center for Biotechnology Information U S National Library of Medicine a b Entrez Gene oncostatin M receptor Mosley B De Imus C Friend D Boiani N Thoma B Park LS Cosman D December 1996 Dual oncostatin M OSM receptors Cloning and characterization of an alternative signaling subunit conferring OSM specific receptor activation The Journal of Biological Chemistry 271 51 32635 43 doi 10 1074 jbc 271 51 32635 PMID 8999038 West NR Owens BM Hegazy AN September 2018 The oncostatin M stromal cell axis in health and disease Scandinavian Journal of Immunology 88 3 e12694 doi 10 1111 sji 12694 PMID 29926972 Machiyama T So T Okuyama Y Kobayashi S Phung HT Asao A Harigae H Ishii N May 2018 TNF receptor associated factor 5 controls oncostatin M mediated lung inflammation Biochemical and Biophysical Research Communications 499 3 544 550 doi 10 1016 j bbrc 2018 03 186 PMID 29596835 Kamiya A Kinoshita T Ito Y Matsui T Morikawa Y Senba E Nakashima K Taga T Yoshida K Kishimoto T Miyajima A April 1999 Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer The EMBO Journal 18 8 2127 36 doi 10 1093 emboj 18 8 2127 PMC 1171297 PMID 10205167 Walker EC Poulton IJ McGregor NE Ho PW Allan EH Quach JM Martin TJ Sims NA April 2012 Sustained RANKL response to parathyroid hormone in oncostatin M receptor deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo Journal of Bone and Mineral Research 27 4 902 12 doi 10 1002 jbmr 1506 PMID 22190112 S2CID 3475348 Blanchard F Wang Y Kinzie E Duplomb L Godard A Baumann H December 2001 Oncostatin M regulates the synthesis and turnover of gp130 leukemia inhibitory factor receptor alpha and oncostatin M receptor beta by distinct mechanisms The Journal of Biological Chemistry 276 50 47038 45 doi 10 1074 jbc M107971200 PMID 11602599 Hunter CA Jones SA May 2015 IL 6 as a keystone cytokine in health and disease Nature Immunology 16 5 448 57 doi 10 1038 ni 3153 PMID 25898198 S2CID 205369252 Heinrich PC Behrmann I Haan S Hermanns HM Muller Newen G Schaper F August 2003 Principles of interleukin IL 6 type cytokine signalling and its regulation The Biochemical Journal 374 Pt 1 1 20 doi 10 1042 bj20030407 PMC 1223585 PMID 12773095 Hermanns HM Radtke S Schaper F Heinrich PC Behrmann I December 2000 Non redundant signal transduction of interleukin 6 type cytokines The adapter protein Shc is specifically recruited to the oncostatin M receptor The Journal of Biological Chemistry 275 52 40742 8 doi 10 1074 jbc M005408200 PMID 11016927 Arita K South AP Hans Filho G Sakuma TH Lai Cheong J Clements S Odashiro M Odashiro DN Hans Neto G Hans NR Holder MV Bhogal BS Hartshorne ST Akiyama M Shimizu H McGrath JA January 2008 Oncostatin M receptor beta mutations underlie familial primary localized cutaneous amyloidosis American Journal of Human Genetics 82 1 73 80 doi 10 1016 j ajhg 2007 09 002 PMC 2253984 PMID 18179886 Walker EC McGregor NE Poulton IJ Solano M Pompolo S Fernandes TJ Constable MJ Nicholson GC Zhang JG Nicola NA Gillespie MT Martin TJ Sims NA February 2010 Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice The Journal of Clinical Investigation 120 2 582 92 doi 10 1172 jci40568 PMC 2810087 PMID 20051625 Komori T Tanaka M Senba E Miyajima A Morikawa Y July 2013 Lack of oncostatin M receptor b leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype The Journal of Biological Chemistry 288 30 21861 75 doi 10 1074 jbc M113 461905 PMC 3724642 PMID 23760275 Tanaka M Hirabayashi Y Sekiguchi T Inoue T Katsuki M Miyajima A November 2003 Targeted disruption of oncostatin M receptor results in altered hematopoiesis Blood 102 9 3154 62 doi 10 1182 blood 2003 02 0367 PMID 12855584 Poling J Gajawada P Richter M Lorchner H Polyakova V Kostin S Shin J Boettger T Walther T Rees W Wietelmann A Warnecke H Kubin T Braun T January 2014 Therapeutic targeting of the oncostatin M receptor b prevents inflammatory heart failure Basic Research in Cardiology 109 1 396 doi 10 1007 s00395 013 0396 3 PMID 24292852 S2CID 21889689 a b Kubin T Poling J Kostin S Gajawada P Hein S Rees W Wietelmann A Tanaka M Lorchner H Schimanski S Szibor M Warnecke H Braun T November 2011 Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling Cell Stem Cell 9 5 420 32 doi 10 1016 j stem 2011 08 013 PMID 22056139 Junk DJ Bryson BL Smigiel JM Parameswaran N Bartel CA Jackson MW July 2017 Oncostatin M promotes cancer cell plasticity through cooperative STAT3 SMAD3 signaling Oncogene 36 28 4001 4013 doi 10 1038 onc 2017 33 PMC 5509502 PMID 28288136 Underhill Day N Heath JK November 2006 Oncostatin M OSM cytostasis of breast tumor cells characterization of an OSM receptor beta specific kernel Cancer Research 66 22 10891 901 doi 10 1158 0008 5472 CAN 06 1766 PMID 17108126 Ng G Winder D Muralidhar B Gooding E Roberts I Pett M Mukherjee G Huang J Coleman N July 2007 Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome The Journal of Pathology 212 3 325 34 doi 10 1002 path 2184 PMID 17516585 S2CID 21134882 Savarese TM Campbell CL McQuain C Mitchell K Guardiani R Quesenberry PJ Nelson BE March 2002 Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas Cytokine 17 6 324 34 doi 10 1006 cyto 2002 1022 PMID 12061840 Kim MS Louwagie J Carvalho B Terhaar Sive Droste JS Park HL Chae YK Yamashita K Liu J Ostrow KL Ling S Guerrero Preston R Demokan S Yalniz Z Dalay N Meijer GA Van Criekinge W Sidransky D August 2009 Promoter DNA methylation of oncostatin m receptor beta as a novel diagnostic and therapeutic marker in colon cancer PLOS ONE 4 8 e6555 Bibcode 2009PLoSO 4 6555K doi 10 1371 journal pone 0006555 PMC 2717211 PMID 19662090 External links editOncostatin M Receptor at the U S National Library of Medicine Medical Subject Headings MeSH This article incorporates text from the United States National Library of Medicine which is in the public domain Retrieved from https en wikipedia org w index php title Oncostatin M receptor amp oldid 1116591806, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.